GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GeneThera Inc (OTCPK:GTHR) » Definitions » Cyclically Adjusted Price-to-FCF

GeneThera (GeneThera) Cyclically Adjusted Price-to-FCF : (As of May. 05, 2024)


View and export this data going back to 2000. Start your Free Trial

What is GeneThera Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


GeneThera Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for GeneThera's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GeneThera Cyclically Adjusted Price-to-FCF Chart

GeneThera Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

GeneThera Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of GeneThera's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, GeneThera's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GeneThera's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GeneThera's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where GeneThera's Cyclically Adjusted Price-to-FCF falls into.



GeneThera Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

GeneThera's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2022 is calculated as:

For example, GeneThera's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2022 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Sep. 2022 (Change)*Current CPI (Sep. 2022)
=0/125.2265*125.2265
=0.000

Current CPI (Sep. 2022) = 125.2265.

GeneThera Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201212 -0.003 96.871 -0.004
201303 0.000 98.209 0.000
201306 0.000 98.518 0.000
201309 -0.004 98.790 -0.005
201312 -0.001 98.326 -0.001
201403 -0.001 99.695 -0.001
201406 0.000 100.560 0.000
201409 -0.001 100.428 -0.001
201412 -0.001 99.070 -0.001
201503 0.000 99.621 0.000
201506 -0.004 100.684 -0.005
201509 -0.023 100.392 -0.029
201512 0.023 99.792 0.029
201603 -0.001 100.470 -0.001
201606 -0.002 101.688 -0.002
201609 0.000 101.861 0.000
201612 -0.001 101.863 -0.001
201703 0.000 102.862 0.000
201706 0.000 103.349 0.000
201709 0.000 104.136 0.000
201712 -0.002 104.011 -0.002
201803 -0.001 105.290 -0.001
201806 -0.004 106.317 -0.005
201809 -0.005 106.507 -0.006
201812 -0.002 105.998 -0.002
201903 0.000 107.251 0.000
201906 0.000 108.070 0.000
201909 0.004 108.329 0.005
201912 -0.005 108.420 -0.006
202003 0.000 108.902 0.000
202006 0.000 108.767 0.000
202009 0.000 109.815 0.000
202012 0.000 109.897 0.000
202103 0.000 111.754 0.000
202106 0.000 114.631 0.000
202109 0.000 115.734 0.000
202112 0.000 117.630 0.000
202203 0.000 121.301 0.000
202206 0.000 125.017 0.000
202209 0.000 125.227 0.000

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


GeneThera  (OTCPK:GTHR) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


GeneThera Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of GeneThera's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


GeneThera (GeneThera) Business Description

Industry
Traded in Other Exchanges
N/A
Address
3051 W 105th Avenue, Suite 350251, Westminster, CO, USA, 80035
GeneThera Inc is a biotechnology company using its proprietary molecular sciences and technologies dedicated to eradicating diseases such as COVID-19, Paratuberculosis, Mad Cow Disease, Chronic Wasting Disease, and E.coli and Salmonella infections. It focuses on developing novel molecular diagnostic tests, therapeutics, and vaccines through its proprietary robotic technologies. Its Molecular Robotic/AI Platform and Therapeutic strategy (MORAPAT) is designed to prevent the spread of disease from animals and at the same time, allow better control of zoonotic infectious agents. The company has also developed a molecular system for the detection of Mycobacterium Avian Paratuberculosis in the milk of infected dairy cows.
Executives
Avel Kolesnikov director 11353 COLONY CIRCLE, BROOMFIELD CO 80020
Mcnece Elmer Roy Jr 10 percent owner 632 CANTRILL DRIVE, DAVIS CA 95616
Fidra Holdings Ltd 10 percent owner CABLE BEACH COURT, ONE WEST BAY STREET, NASSAU BAHAMAS C5 00000
Steven Michael Grubner director, officer: Chief Financial Officer 728 S. PRAIRIE AVENUE, BARRINGTON IL 60010
Antonio Milici director, 10 percent owner, officer: Chief Executive Officer 3930 YOUNGFIELD, WHEAT RIDGE CO 80033
Tannya L Irizarry director, 10 percent owner, officer: Chief Administative Officer 11880 ANTLER TR, LITTLETON CO 80127

GeneThera (GeneThera) Headlines

No Headlines